These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 20819765)

  • 1. [Clinical end-points and surrogate markers of pulmonary arterial hypertension in the light of evidence-based treatment].
    Can MM; Kaymaz C
    Anadolu Kardiyol Derg; 2010 Aug; 10 Suppl 1():36-42. PubMed ID: 20819765
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Surrogate end points for pulmonary arterial hypertension.
    Kawut SM; Palevsky HI
    Am Heart J; 2004 Oct; 148(4):559-65. PubMed ID: 15459583
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Biological serum markers in the management of pediatric pulmonary arterial hypertension.
    Van Albada ME; Loot FG; Fokkema R; Roofthooft MT; Berger RM
    Pediatr Res; 2008 Mar; 63(3):321-7. PubMed ID: 18287971
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Investigation of pulmonary hypertension].
    Natali D; Simonneau G; Humbert M; Montani D
    Rev Pneumol Clin; 2008 Jun; 64(3):151-61. PubMed ID: 18656791
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pulmonary arterial hypertension: evaluation of the newly diagnosed patient.
    Torbicki A; Kurzyna M
    Semin Respir Crit Care Med; 2005 Aug; 26(4):372-8. PubMed ID: 16121313
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Medical treatment of pulmonary arterial hypertension.
    Adamali H; Gaine SP; Rubin LJ
    Semin Respir Crit Care Med; 2009 Aug; 30(4):484-92. PubMed ID: 19634087
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Management of dyspnea in advanced pulmonary arterial hypertension.
    Sajkov D; Petrovsky N; Palange P
    Curr Opin Support Palliat Care; 2010 Jun; 4(2):76-84. PubMed ID: 20407377
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostication in pulmonary arterial hypertension.
    Agarwal R; Gomberg-Maitland M
    Heart Fail Clin; 2012 Jul; 8(3):373-83. PubMed ID: 22748900
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Surrogate and combined end points in pulmonary arterial hypertension.
    Ventetuolo CE; Benza RL; Peacock AJ; Zamanian RT; Badesch DB; Kawut SM
    Proc Am Thorac Soc; 2008 Jul; 5(5):617-22. PubMed ID: 18625754
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Continuous hemodynamic monitoring in patients with pulmonary arterial hypertension.
    Frantz RP; Benza RL; Kjellström B; Bourge RC; Barst RJ; Bennett TD; McGoon MD
    J Heart Lung Transplant; 2008 Jul; 27(7):780-8. PubMed ID: 18582809
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Six-minute walk distance as parameter of functional outcome after pulmonary endarterectomy for chronic thromboembolic pulmonary hypertension.
    Reesink HJ; van der Plas MN; Verhey NE; van Steenwijk RP; Kloek JJ; Bresser P
    J Thorac Cardiovasc Surg; 2007 Feb; 133(2):510-6. PubMed ID: 17258590
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical trial designs in PAH: shifting from functional measurements to long-term clinical outcomes.
    Studer SM; Gilkin RJ
    Am J Manag Care; 2014 Mar; 20(6 Suppl):S115-22. PubMed ID: 24716456
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Endpoints in pulmonary arterial hypertension: the role of clinical worsening.
    Peacock A; Keogh A; Humbert M
    Curr Opin Pulm Med; 2010 May; 16 Suppl 1():S1-9. PubMed ID: 20375659
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High N-terminal pro-brain natriuretic peptide levels and low diffusing capacity for carbon monoxide as independent predictors of the occurrence of precapillary pulmonary arterial hypertension in patients with systemic sclerosis.
    Allanore Y; Borderie D; Avouac J; Zerkak D; Meune C; Hachulla E; Mouthon L; Guillevin L; Meyer O; Ekindjian OG; Weber S; Kahan A
    Arthritis Rheum; 2008 Jan; 58(1):284-91. PubMed ID: 18163505
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Seven years of experience in patients with pulmonary arterial hypertension in Ege University Hospital: diagnostic approach of a single center].
    Kayikçioğlu M; Kültürsay H
    Anadolu Kardiyol Derg; 2008 Aug; 8(4):279-85. PubMed ID: 18676304
    [TBL] [Abstract][Full Text] [Related]  

  • 16. How has epoprostenol changed the outcome for patients with pulmonary arterial hypertension?
    Barst R
    Int J Clin Pract Suppl; 2010 Nov; (168):23-32. PubMed ID: 20939843
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term treatment with oral sildenafil is safe and improves functional capacity and hemodynamics in patients with pulmonary arterial hypertension.
    Michelakis ED; Tymchak W; Noga M; Webster L; Wu XC; Lien D; Wang SH; Modry D; Archer SL
    Circulation; 2003 Oct; 108(17):2066-9. PubMed ID: 14568893
    [TBL] [Abstract][Full Text] [Related]  

  • 18. End-points and clinical trial design in pulmonary arterial hypertension: have we made progress?
    Peacock AJ; Naeije R; Galiè N; Rubin L
    Eur Respir J; 2009 Jul; 34(1):231-42. PubMed ID: 19567606
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Endothelin receptor antagonists in pulmonary arterial hypertension].
    Tokgöz HC; Can MM; Kaymaz C
    Anadolu Kardiyol Derg; 2010 Sep; 10 Suppl 2():9-15. PubMed ID: 20819750
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy of sildenafil as a rescue therapy for patients with severe pulmonary arterial hypertension and given long-term treatment with prostanoids: 2-year experience.
    Ruiz MJ; Escribano P; Delgado JF; Jiménez C; Tello R; Gómez MA; de la Calzada CS
    J Heart Lung Transplant; 2006 Nov; 25(11):1353-7. PubMed ID: 17097500
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.